CHICAGO, Sept. 7, 2017 /PRNewswire/ — BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. […]